Article
It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.
All News
Dr. John Cush
Tweet
Immune Dimming or Immune Reset in RA: How Far Should We Go?
CD19 CAR T-cell therapy has moved from oncology to autoimmune disease after SLE reports of sustained drug-free remission suggesting an immune reset. This raises whether profound depletion is needed or if milder https://t.co/WONQmhs86j
Md Yuzaiful Md Yusof
Tweet
#EULAR2026 Please find my video on deep tissue depletion and associated histological remission following treatment with Obinutuzumab in #lupus nephritis @RheumNow
https://t.co/V9CNdPsLcV https://t.co/WLVFyaSSUE
Janet Pope
Tweet
Good performance of #definite
#antisynthetase #syndrome
✅+antibody mandatory
Possible also does ok
@RheumNow #EULAR2026
June 6 #antisynthetase #classifiaction #criteria https://t.co/5sxogTX9YT
Mrinalini Dey
Tweet
#OP0159 #EULAR2026
Multimodal study in D2T RA identified altered brain connectivity patterns linked to pain, psychological features & peripheral transcriptomics. Supports neuroimmune component in D2T RA & need for personalised approaches beyond inflammation control. @RheumNow https://t.co/qMQbkiMCwX
Md Yuzaiful Md Yusof
Tweet
#EULAR2026 POS1139 Pay attention in #SLE with anti-Sm+ RNP+. Data from 3 RCTs & a cohort:
-enriched in Black patients
-poor response to B-cell depletion inc. Obi
-non-response is assoc. with BAFF-dependent B-cell repopulation. So, use Belimumab
-High ferritin = flare @RheumNow https://t.co/3uDMigY8i2
Mrinalini Dey
Tweet
Comorbidities don’t just impact prognosis, remission and treatment in RA- they impact mortality. Comorbidities cannot be treated in a “one size fits all” approach; they should be assessed and managed on an individual basis.
@ElenaNikiUK
@RheumNow #EULAR2026 https://t.co/UmB63QBl7N
Nelly ZIADE 🍀
Tweet
Do probiotics improve disease activity in PsA?
POS0290: no
MEDISPA RCT n=66
Multispecies probiotics not superior to placebo at week 12
#EULAR2026 @RheumNow https://t.co/1byJ1nB4GF
Antoni Chan MD (Prof)
Tweet
Abstr LB0004
CC312 is a CD19/CD3/CD28 tri-specific T cell engager and sustains SRI-4 responses beyond one year with rapid, deep B-cell depletion in autoimmune diseases. Not CAR-T. Not a conventional biologic. A T cell engager that redirects your own immune cells to deplete B https://t.co/rTs3Rg7BPe
Dr. John Cush
Tweet
All content is independently chosen and produced by the RheumNow faculty. Our expanded #EULAR2026 coverage is made possible by support from Bristol Myers Squibb and UCB.
Md Yuzaiful Md Yusof
Tweet
#EULAR2026 LB0004 First BiTE, now TriTE! Tri-specific CC312 CD19/CD3/CD28 (i.e. CD28 co-stimulates Tcell activation) showed deep Bcell depletion, early efficacy & safety in 10 #SLE patients up to 52WKs. Promising but longer FU needed to see if repeat dosing needed @RheumNow https://t.co/6Lbm9LYJrY
sheila
Tweet
JASMINE-SLE: Proof of concept study on
Nipocalimab for SLE
SRI-4 met at wk 24 for the 15 mg/kg q2w dose va. PBO
Improvement of SRI-4 composite & LLDAS at wk 52
LB0007 @RheumNow #EULAR2026 https://t.co/0wzHyid3dy
Janet Pope
Tweet
5 top abstracts in #Myositis @eular_org
1 #Nailfold #capillaries as an early marker of #IIM Rx
2 #brepocitinib +RCT #DM
3 & rapid skin improvement #CLASI
4 #Ab may help #IBM but neg primary endpoint
5 #criteria for #antisynthetase
#EULAR2026 @RheumNow
OP0168, 0166, 0164 POS264
Janet Pope
Tweet
Top 5 abst in #SjD
#anifrolumab +RCT
#ianalumab LTE Rx sustained
#telitatacept +LTE
#iana improves u/s parotids
#TYK2 sig in#SjD
OP0002, 0126, 127, 160 POS0284
#EULARbest #EULAR2026
@RheumNow @eular_org
Janet Pope
Tweet
Do you target #DORIS / remission in #SLE pts
#EULAR2026 @RheumNow @eular_org
Janet Pope
Tweet
#antisynthetase #EULAR/ACR #classification #criteria
#EULAR2026
@RheumNow
Based on >2k pts
Probable v definite
Ignore low + #synthetase #antibodies
Seems reasonable and applicable
➡️my opinion https://t.co/MyCRiCSiGo
Janet Pope
Tweet
Do you routinely recommend #herpes #zoster #vaccination in all #immune #suppressed pts?
#EULAR2026 @RheumNow
#vaccination #guidelines
Mrinalini Dey
Tweet
#OP0207 #EULAR2026: SUPERFIBRES trial suggests dietary fibre supplementation may enhance MTX response in RA. Inulin improved EULAR responses and Th17/Treg balance over 30 days, with strongest effects seen in MTX-treated patients. Fascinating microbiome-linked signal. @RheumNow https://t.co/nCvZlooamF
Janet Pope
Tweet
Is there enough data to recommend
#rituximab
For #ILD in #rheumatoid #arthritis
@RheumNow #EULAR2026
Mrinalini Dey
Tweet
Catching up on #EULAR2026 “Advanced management in RA” session: #OP0202 reported positive phase 2b RENOIR data for rosnilimab, a selective pathogenic T-cell depleter, with significant improvements in DAS28-CRP, ACR responses and CDAI LDA vs placebo in RA. @RheumNow https://t.co/IKKtakxpya
